HealthEquity (HQY)
(Delayed Data from NSDQ)
$55.10 USD
-1.02 (-1.82%)
Updated May 26, 2023 04:00 PM ET
After-Market: $55.07 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
HealthEquity (HQY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$80.08 | $94.00 | $67.00 | 42.69% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for HealthEquity comes to $80.08. The forecasts range from a low of $67.00 to a high of $94.00. The average price target represents an increase of 42.69% from the last closing price of $56.12.
Analyst Price Targets (13)
Broker Rating
HealthEquity currently has an average brokerage recommendation (ABR) of 1.46 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.46 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, nine are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 69.23% and 15.38% of all recommendations. A month ago, Strong Buy made up 69.23%, while Buy represented 15.38%.
Broker Rating Breakdown

Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 10 | 10 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.46 | 1.46 | 1.46 | 1.43 | 1.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
12/7/2022 | Guggenheim Securities | Alexander Y Draper | Strong Buy | Strong Buy |
10/17/2022 | Barrington Research | Alexander P Paris | Strong Buy | Strong Buy |
9/16/2022 | KeyBanc Capital Markets | Scott Schoenhaus | Strong Buy | Strong Buy |
9/12/2022 | Raymond James | Charles G Peters | Moderate Buy | Moderate Buy |
9/7/2022 | Robert W. Baird & Co. | Mark S Marcon | Not Available | Hold |
8/30/2022 | SVB Securities | Stephanie Davis | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.46 |
ABR (Last week) | 1.46 |
# of Recs in ABR | 13 |
Average Target Price | $80.08 |
LT Growth Rate | 21.10% |
Industry | Medical Services |
Industry Rank by ABR | 113 of 252 |
Current Quarter EPS Est: | 0.41 |